Takeda Pharmaceutical Co. $TAK Stock Purchased by Quadrant Capital Group LLC

Quadrant Capital Group LLC boosted its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 67.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 136,966 shares of the company’s stock after purchasing an additional 55,360 shares during the quarter. Quadrant Capital Group LLC’s holdings in Takeda Pharmaceutical were worth $2,537,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. SHP Wealth Management bought a new position in shares of Takeda Pharmaceutical in the fourth quarter valued at approximately $42,000. Nisa Investment Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 28.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,306 shares of the company’s stock worth $42,000 after buying an additional 515 shares during the period. TD Waterhouse Canada Inc. bought a new stake in shares of Takeda Pharmaceutical during the 3rd quarter worth $59,000. Rockefeller Capital Management L.P. boosted its holdings in shares of Takeda Pharmaceutical by 30.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company’s stock worth $81,000 after buying an additional 1,215 shares during the period. Finally, Valeo Financial Advisors LLC acquired a new position in Takeda Pharmaceutical in the 2nd quarter valued at $163,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Insider Buying and Selling at Takeda Pharmaceutical

In related news, insider Andrew Plump sold 165,393 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $2,828,220.30. Following the transaction, the insider owned 766,569 shares of the company’s stock, valued at approximately $13,108,329.90. The trade was a 17.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Lauren Duprey sold 47,586 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $813,720.60. Following the transaction, the insider owned 226,057 shares of the company’s stock, valued at approximately $3,865,574.70. The trade was a 17.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 627,457 shares of company stock valued at $10,981,175 in the last three months. 0.04% of the stock is owned by insiders.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $19.95 on Thursday. The business has a 50 day moving average price of $18.51 and a 200 day moving average price of $17.30. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $20.13. The company has a market cap of $63.94 billion, a price-to-earnings ratio of 58.69 and a beta of -0.07. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.41 by $0.54. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. The company had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Research analysts predict that Takeda Pharmaceutical Co. will post 1.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on TAK. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Zacks Research lowered shares of Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 1st. Finally, Weiss Ratings raised shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.